Sudden cardiac death in athletes : the Lausanne recommendations

La mort subite d'origine cardiaque chez les sportifs : les Recommandations de Lausanne Résumé Objectifs : Cette étude collecte les données de la littérature scientifique concernant la mort subite d'origine cardiaque chez les sportifs et a pour but d'aboutir à un protocole d'investigation de préparticipation globalement acceptable, approuvé par la conférence de consensus du Comité International Olympique(CIO), et recommandé par ce dernier. Données cliniques : La mort subite chez les athlètes de moins de 35 ans, engagés dans des sports de compétition,. est un évènement bien connu, dont l'incidence est plus élevée (~2/100000/an) que chez les non-athlètes (2,5 :1). La cause est cardiovasculaire dans plus de 90% des cas. Méthodes : Une revue systématique de la littérature a mis en évidence les causes de mort subite d'origine cardiaque, le sexe, l'âge, les maladies cardiaques sous-jacentes et le type de sport, ainsi que les protocoles d'investigation de préparticipation utilisés. Les méthodes nécessaires pour détecter des anomalies cardiaques préexistantes sont discutées pour formuler un protocole d'investigation de préparticipation pour la commission médicale du CIO. (http://www.olympic.org/uk/organisation/commissions/medical/full_ story_ uk.asp?id=1182) Résultats: 1101 cas de mort subite d'origine cardiaque ont été rapportés (1966-2004) chez des athlètes de moins de 35 ans, 50% présentant des anomalies cardiaques congénitales et des cardiomyopathies et 10% une athérosclérose à début précoce. 40% des athlètes avaient moins de 18 ans, 33% moins de 16 ans ; le rapport femme/homme était de 1/9. La mort subite d'origine cardiaque était reportée dans presque tous les sports ; ceux impliqués le plus fréquemment étaient le football(30%), le basketball(25%), et la course à pied(15%). Les tests de préparticipation étaient de qualité et de contenu variables. La conférence de consensus du CIO a accepté les «Recommandations de Lausanne » proposées, basées sur cette recherche et des opinions d'experts. (http://multimedia.olympic.org/pdf/en_report_886.pdf) Conclusions : La mort subite d'origine cardiaque touche plus souvent qu'attendu les jeunes athlètes et est principalement due à des anomalies cardiaques congénitales préexistantes. Les atteintes athérosclérotiques précoces forment une autre cause importante de décès chez les jeunes adultes. L'acceptation par le CIO de «Recommandations de Lausanne » a permis d'aboutir à un protocole d'investigation de préparticipation globalement acceptable .

Lack of Enantioselectivity in the SULT1A3-catalyzed Sulfoconjugation of Normetanephrine Enantiomers: An In Vitro and Computational Study.

(1R)-Normetanephrine is the natural stereoisomeric substrate for sulfotransferase 1A3 (SULT1A3)-catalyzed sulfonation. Nothing appears known on the enantioselectivity of the reaction despite its potential significance in the metabolism of adrenergic amines and in clinical biochemistry. We confronted the kinetic parameters of the sulfoconjugation of synthetic (1R)-normetanephrine and (1S)-normetanephrine by recombinant human SULT1A3 to a docking model of each normetanephrine enantiomer with SULT1A3 and the 3'-phosphoadenosine-5'-phosphosulfate cofactor on the basis of molecular modeling and molecular dynamics simulations of the stability of the complexes. The K(M) , V(max) , and k(cat) values for the sulfonation of (1R)-normetanephrine, (1S)-normetanephrine, and racemic normetanephrine were similar. In silico models were consistent with these findings as they showed that the binding modes of the two enantiomers were almost identical. In conclusion, SULT1A3 is not substrate-enantioselective toward normetanephrine, an unexpected finding explainable by a mutual adaptability between the ligands and SULT1A3 through an "induced-fit model" in the catalytic pocket. Chirality, 00:000-000, 2012.© 2012 Wiley Periodicals, Inc.

Chemical Functionalization of Bioceramics To Enhance Endothelial Cells Adhesion for Tissue Engineering.

To control the selective adhesion of human endothelial cells and human serum proteins to bioceramics of different compositions, a multifunctional ligand containing a cyclic arginine-glycine-aspartate (RGD) peptide, a tetraethylene glycol spacer, and a gallate moiety was designed, synthesized, and characterized. The binding of this ligand to alumina-based, hydroxyapatite-based, and calcium phosphate-based bioceramics was demonstrated. The conjugation of this ligand to the bioceramics induced a decrease in the nonselective and integrin-selective binding of human serum proteins, whereas the binding and adhesion of human endothelial cells was enhanced, dependent on the particular bioceramics.

Covalent cell surface functionalization of human fetal osteoblasts for tissue engineering.

The chemical functionalization of cell-surface proteins of human primary fetal bone cells with hydrophilic bioorthogonal intermediates was investigated. Toward this goal, chemical pathways were developed for click reaction-mediated coupling of alkyne derivatives with cellular azido-expressing proteins. The incorporation via a tetraethylene glycol linker of a dipeptide and a reporter biotin allowed the proof of concept for the introduction of cell-specific peptide ligands and to follow the reaction in living cells. Tuning the conditions of the click reaction resulted in chemical functionalization of living human fetal osteoblasts with excellent cell survival.

Surface modification of biomaterials for conjugation with human fetal osteoblasts.

Surface functionalization of hydroxyapatite (HA) and beta-tricalcium phosphate (TCP) bioceramics with chemical ligands containing a pyrrogallol moiety was developed to improve the adhesion of bone cell precursors to the biomaterials. Fast and biocompatible copper-free click reaction with azido-modified human fetal osteoblasts resulted in improved cell binding to both HA and TCP bioceramics, opening the way for using this methodology in the preparation of cell-engineered bone implants.

The prolyl-aminodipeptidases and their inhibitors as therapeutic targets for fibrogenic disorders

Many biologically active peptides are protected from general proteolytic degradation by evolutionary conserved prolines (Pro), due to conformational constraints imposed by the Pro residue. Thus the biological importance of prolyl-specific peptidases points to a high potential for drug discovery for this family of enzymes. Panels of inhibitors have been synthesized and their effects, determined in biological models, suggest the inhibition of families of enzymes with similar activities. Prolyl-specific aminodipeptidases include dipeptidyl-aminodipeptidase IV (DPP IV)/CD26, DPP8, DPP9 and fibroblast activation protease-alpha (FAP-alpha)/seprase, able to release X-Pro dipeptides from the N-terminus of peptides. DPP IV inhibitors are in clinical use for type 2 diabetes. In this review, the expression and the potential functions of prolyl-aminodipeptidases are reviewed in diseases, and the inhibitors developed for these enzymes are discussed, with a specific focus on inhibitors able to discriminate between DPP IV and fibroblast activation protease-alpha (FAPalpha)/seprase as potential leads for the treatment of fibrogenic diseases.